Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Xigris
Active Ingredient: Drotrecogin alfa, activated 20mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: DSM Pharmaceuticals Inc., Greenville, North Carolina, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Product: Xigris
Active Ingredient: Drotrecogin alfa, activated 5mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: DSM Pharmaceuticals Inc., Greenville, North Carolina, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 13th day of September 2002.
DR. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997.